Aggressive B- Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
Laurie Sehn
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Man
...view more
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.
This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.
https://www.us.elsevierhealth.com/aggressive-b-cell-lymphoma-an-issue-of-hematologyoncology-clinics-of-north-america-9780323477413.html2471Aggressive B- Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9780323477413.jpg81.74108.99USDInStock/Medicine/Hematology/Clinics/Clinics13743887255255041This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more. This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.00add-to-cart97803234774132016ProfessionalBy Laurie Sehn, MD20161Book152w x 229hElsevier0Dec 5, 2016IN STOCK - This may take up to 5 business days to shipBy <STRONG>Laurie Sehn</STRONG>, MD, BC Cancer AgencyClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
